COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

                Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024

Company ended the quarter with US$27.8 million in cash        

Read more at globenewswire.com